Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

A Prospective Randomized Study Comparing Time to Ambulation, Time to Hemostasis and Safety Using a Closure Device Alone an in Conjunction With a Potassium Ferrate Pad Following Transfemoral Catheterization

ID
Name
22-000700
Description
The purpose of this clinical study is to compare how well two different devices for achieving hemostasis perform in patients undergoing transfemoral procedures with 6 French Access. Both devices are approved by the FDA for this use, and have already been used by clinicians on patients undergoing transfemoral procedures. It is believed that the use of both devices in combination compared to the Perclose alone will shorten the time that it takes to 'seal' the artery, resulting in a shorter period of time that patients would need to lay flat.
Trial arms
Trial start
2022-08-01
Estimated PCD
2024-06-01
Trial end
2024-07-01
Status
Recruiting
Treatment
Perclose
Patients will have a PercloseTM device deployed at the arteriotomy. Manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed or per protocol under the disgression of the operator will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
Arms:
Perclose Only, Perclose with Statseal Device
Other names:
Suture based hemostasis device
Statseal
Patients will have a PercloseTM device deployed at the arteriotomy. A Statseal disc will applied and manual pressure will be held for at least one minute, the beginning of which will correspond to time point zero. Patent hemostasis will be documented after device deployment. Any manual compression needed will count towards the time to hemostasis. After hemostasis is achieved in the cath lab the patient will be sent to the post-operative area for monitoring. If any additional bleeding is appreciated, manual compression will again be held. Two hours after the patient has had the PercloseTM device deployed the patient will ambulate. If any new bleeding from the puncture site or under the skin the patient will again lay supine and at least 10 minutes of manual pressure will be held and the an ambulation trial will be attempted at least 30 minutes after the subsequent trial. This will be continued until the patient has no bleeding at the time of ambulation.
Arms:
Perclose with Statseal Device
Other names:
potassium ferrate disc with topical hydrophilic polymer
Size
150
Primary endpoint
Time to Ambulation
Within 30 minutes of discharge or 24 hours post procedure (± 1 hour), whichever occurs first.
Eligibility criteria
Inclusion Criteria: * Patient undergoing diagnostic angiography or PCI with femoral access who undergo PercloseTM closure. * Catheterization with a 6Fr system * Those with a planned radial approach will also be enrolled given the possibility of changing to femoral access in the catheterization lab if radial access is not possible given radial artery spasm, significant patient discomfort with a contraindication to greater levels of sedation, inability to transverse guidewire into the aortic root, inability to engage coronary artery or deliver equipment, or other clinically indicated reason. Exclusion Criteria: - Candidates for this study will be excluded if any one of the following criteria is true: * Use of a hemostasis method or device besides PercloseTM (Perclose may not be used in situations of heavy calcification, presence of dissection, etc). * Patients undergoing catheterization only from the radial, brachial, ulnar, or distal radial (snuffbox) artery approach. * Use of an anticoagulant other than unfractionated heparin or bivalirudin. * Any use of glycoprotein inhibitors or cangrelor. * Use of sheathless guides. * Any anticipated need for continued anticoagulation post-catheterization, including extended bivalirudin infusion. * Any active treatment with oral anticoagulants continued during course of procedure. * Presence of arteriovenous dialysis fistula in the ipsilateral leg. * Any physical deformity or trauma / injury of the leg that would prevent proper placement or function of the hemostasis band. * Inability of the patient to personally consent for the study. (no surrogate consent) * Cardiogenic shock, emergent procedures (high risk myocardial infarctions), or any clinical instability as assessed by the physician performing the procedure.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 150, 'type': 'ESTIMATED'}}
Updated at
2023-08-01

1 organization

1 product

4 indications

Organization
University of California, Los Angeles
Product
Statseal
Indication
Arterial occlusion
Indication
Cardiovascular Diseases
Indication
Atherosclerosis
Indication
Hematoma